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Abstract
Objectives Willingness-to-pay (WTP) provides a broad assessment
of well-being, capturing beneﬁts beyond health. However, the valid-
ity of the approach has been questioned and the evidence relating to
the sensitivity of WTP to changes in health status is mixed. Using
menorrhagia (heavy menstrual bleeding) as a case study, this
exploratory study assesses the sensitivity to scale of WTP to change
in health status as measured by a condition-speciﬁc measure,
MMAS, which includes both health and non-health beneﬁts. The
relationship between EQ-5D and change in health status is also
assessed.
Methods Baseline EQ-5D and MMAS values were collected from
women taking part in a randomized controlled trial for pharmaceuti-
cal treatment of menorrhagia. Following treatment, these measures
were administered along with a WTP exercise. The relationship
between the measures was assessed using Spearman’s correlation
analysis, and the sensitivity to scale of WTP was measured by identi-
fying diﬀerences in WTP alongside diﬀerences in MMAS and EQ5D
values.
Results Our exploratory ﬁndings indicated that WTP, and not EQ-
5D, was signiﬁcantly positively correlated with change in MMAS,
providing some evidence for convergent validity. These ﬁndings sug-
gest that WTP is capturing the non-health beneﬁts within the
MMAS measure. Mean WTP also increased with percentage
improvements in MMAS, suggesting sensitivity to scale.
Conclusion When compared to quality of life measured using the
condition-speciﬁc MMAS measure, the convergent validity and sen-
sitivity to scale of WTP is indicated. The ﬁndings suggest that WTP
is more sensitive to change in MMAS, than with EQ-5D.
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Introduction
Contingent valuation is a method for assigning
monetary values to non-market goods, such as
health-care interventions, for use as an outcome
measure within cost–beneﬁt analysis (CBA).
Willingness-to-pay (WTP) is the most commonly
used contingent valuation approach and pro-
vides an overall measure of strength of
preference expressed in monetary terms. Using
this approach, individuals are asked to consider
hypothetical scenarios that describe both the
process and outcome of the health-care interven-
tion and asked to state maximum WTP for the
health care good being valued. Sample average
WTP values are typically used as an indication
of strength of preference and can be directly
compared to assess the value of alternative
health-care interventions. In a similar way to
how EQ-5D is used to inform the outcome mea-
sure for cost–utility analysis (CUA), WTP can
also be used to inform the outcome for a CBA.
Used in this way, it becomes a generic measure
of value for treatment or services and is thus
weighed against cost to measure overall cost-
eﬀectiveness. Depending on the ratio between
the incremental diﬀerence in costs and beneﬁts
(WTP) of alternative treatment options, judge-
ments can then be made by decision makers on
whether to recommend the treatment/service
based on this ratio. WTP encapsulates both
health and non-health aspects of well-being, the
advantages of such an approach are ever more
recognized, particularly because the National
Institute for Health and Care Excellence are
now also commissioning across public health
and social care.1 Despite this, there are key limi-
tations to the WTP approach including the
diﬃculty with contemplating the hypothetical
survey scenario, and the lack of well-deﬁned
preferences when individuals are unfamiliar with
the goods they are asked to value. The literature
also refers to evidence on strategic bias and
questions about the validity of the approach.2
The objective of this exploratory study was to
examine the validity of the WTP approach using
treatment for heavy menstrual bleeding (clini-
cally termed menorrhagia) as a case example.
Menorrhagia is a chronic condition with episodic
symptoms which is known to aﬀect both health
and non-health aspects of life. Generic quality of
life measures, such as EQ-5D and SF-6D, that
are focused on health alone are recommended
for use in health care to be used to capture the
impact of conditions. The advantage of these
generic measures is that they enable comparison
of eﬀectiveness across diﬀerent treatment condi-
tions as the outcomes are measured using one
commensurate unit. An interesting feature of
menorrhagia is the condition’s chronic but
episodic nature as the symptoms occur for
approximately 1 week every month which has
implications for the timing of assessment when
using generic measures with standard recall peri-
ods.3 In terms of validity, within the context of
menorrhagia the condition-speciﬁc quality of life
measure, MMAS (menorrhagia multi-attribute
scale described in detail below), is considered to
be the gold standard measure.4 Whilst condition-
speciﬁc measures can be more sensitive than gen-
eric measures, their use in decision making is
limited due to the lack of comparability across
conditions. There are several types of validity
that one can assess including content validity
(whether all relevant aspects of the condition are
considered in the instrument), construct validity
(determines whether an underlying relationship
exists between questions in the instrument and an
attribute that is measured), and criterion validity
(whether one attribute or set of attributes predicts
an outcome based on information from other attri-
butes).5,6 The focus of this paper is construct
validity, or more speciﬁcally convergent validity
which is the degree to which two theoretically
equivalent measures converge, and within the
context of contingent valuation, it is often
referred to as sensitivity to scale or scope.7
This question is of theoretical relevance as
many studies have shown that WTP demon-
strates theoretical validity with WTP increasing
with income,8 and others have focused on con-
vergent validity with other preference elicitation
measures such as time trade-oﬀ (TTO) and stan-
dard gamble (SG).9 The evidence on convergent
validity within the health-care sector and sensi-
tivity to the size of the beneﬁt is mixed 9,10 and in
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particular, the evidence relating to the sensitivity
of WTP to changes in health status 9 is far from
conclusive. In theory, the respondent’s percep-
tion of the value of a treatment should be
sensitive to changes in the size of the beneﬁt
derived from the treatment. For example, WTP
demonstrates convergent validity if the WTP
increases with a perception of greater improve-
ment in treatment beneﬁt. This study presented
a unique opportunity to assess the sensitivity of
WTP longitudinally as both EQ5D and MMAS
data were collected at diﬀerent time points,
along with WTP. The sensitivity to scale of WTP
can therefore be assessed in relation to EQ5D
and MMAS over time.
First, we assessed the change in condition-
speciﬁc quality of life following treatment for
menorrhagia, as measured by MMAS, against
the WTP for this change in outcome, and sec-
ond, we assessed the underlying relationship
between WTP and general health-related quality
of life when measured using EQ-5D.
Methods
We carried out the exploratory study with
women who were already participating in the
NIHR funded ECLIPSE trial (ISRCTN
86566246).11 Ethical approval was obtained
from the National Research Ethics Service Com-
mittee South West-Exeter and clinical trial
authorization from the Medicines and Health-
care Regulatory Authority. Written consent was
obtained from the participants.
Study population
The ECLIPSE trial is a pragmatic, multicentre,
randomized trial, comparing the clinical and
cost-eﬀectiveness of levonorgestrel-releasing
intrauterine device (LNG-IUS) against usual
medical treatment in the primary care set-
ting.11,12 Women between 25 and 50 years of age
that presented to their general practitioner (GP)
with menorrhagia, occurring over at least three
consecutive cycles, were randomized to a treat-
ment group by telephone or web-based central
randomization service. Women were excluded if
they intended to become pregnant over the next
5 years, were taking hormone replacement ther-
apy or tamoxifen, had intermenstrual or post-
coital bleeding or examination suggestive of
ﬁbroids (abdominally palpable uterus equivalent
in size to 10–12 weeks of gestation) or other
pathologies, or had contraindications to, or a
preference for, LNG-IUS or usual medical treat-
ments. The pharmaceutical treatments were
either the LNG-IUS (termed Mirena in the ques-
tionnaire) or usual medical treatment (oral
treatment), which can include tranexamic acid,
mefenamic acid, combined oral contraceptive or
Depo-Provera.
Data collection
Data were collected at baseline and once symp-
toms had stabilized with treatment (‘post-initial
treatment eﬀectiveness’). As the study is nested
within the ECLIPSE trial, ECLIPSE trial data
collection forms were used to collect baseline
data. For the post-initial treatment eﬀectiveness
data collection and for the purposes of this
study, we adapted the ECLIPSE trial forms by
adding an additional WTP question. Both ques-
tionnaires were sent to women in the ECLIPSE
trial for completion.
ECLIPSE trial baseline questionnaire
As part of the trial, follow-up women were asked
to complete the condition-speciﬁc measure
MMAS and the generic health-related quality of
life measure EQ-5D-3L. The instruments had
the following properties:
1. MMAS. MMAS is a self-report questionnaire
that has six attributes including ‘practical dif-
ﬁculties’, ‘social life’, ‘psychological health’,
‘physical health and well-being’, ‘work/daily
routine’ and ‘family life/relationships’. Each
attribute has four levels ranging from unaf-
fected to severely aﬀected. For example, the
wording for social life relating to severely
aﬀected reads ‘My social life is devastated
during my cycle. I am unable to make any
plans’. The questions refer to ‘during my
cycle’, and the respondent ticks the level that
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most accurately reﬂects their experience. The
measure is scored on a 0–100 scale, with 0
being worst possible state for the condition
and 100 being best possible state. Each attri-
bute has been weighted according to the
menorrhagia patients’ preferences using 21
counters, which are considered to be impor-
tance points. The visual analogue scale
(0–100) is then used to weight the relative
importance of the levels within the attribute.
The weighting for the levels is then multiplied
by the weighting for the attribute. The overall
score is then derived by summing the value of
the levels ticked by the respondent to provide
an overall score between 0 and 100.13
2. EQ-5D-3L. EQ-5D is a generic measure of
health outcome that can be used across a
range of conditions. Its ﬁve attributes include
‘mobility’, ‘self-care’, ‘usual activities’, ‘pain/
discomfort’ and ‘Anxiety/depression’ The
attributes each have three levels and the ques-
tions are asked with reference to ‘health
today’. Responses to the instrument can be
used to generate a health-related quality of
life score referred to as a ‘utility’ value
expressed on a scale where 0 represents death,
values below zero worse than death and 1
indicates full health.
Post-initial treatment eﬀectiveness questionnaire
The questionnaire booklets that were designed
for the purpose of this study were posted in
August 2012 to all eligible women in the
ECLIPSE trial. This time point captured women
who were either 2 or 5 years post-initial treat-
ment eﬀectiveness, due to the 3-year time period
for recruitment into the trial. By post, women
received (1) a patient information sheet outlining
the purpose of the work and; (2) an ‘ex-post’
(post-initial treatment eﬀectiveness) question-
naire; and (3) a prepaid stamped addressed
envelope to return the completed questionnaire.
The objective of the ex-post questionnaire was
to elicit a WTP value for the pharmaceutical
treatment that the women were currently taking,
either LNG-IUS or oral treatment. In this con-
text therefore, average maximum WTP values
were derived after the change in outcome had
occurred, from respondents who had experience
of the condition and experience of the treatment.
Hence, WTP was elicited from the ex-post per-
spective. The WTP value therefore reﬂected the
direction and level of change in outcome over
time in response to treatment. It is a commonly
practiced approach to consider use value when
eliciting WTP in health care.14–16
Maximum WTP values were elicited for both
LNG-IUS and oral treatment using the self-
complete ex-post booklet questionnaire. The
booklet was similar in design to the trial
questionnaire and captured data on condition-
speciﬁc quality of life (MMAS), WTP, socio-
demographic details and health-related quality
of life using the EQ-5D-3L.
The MMAS was ﬁrst presented in the question-
naire, followed by questions to determine current
and previous treatment taken as part of the
ECLIPSE trial. Respondents were asked for their
maximum monthly out of pocket WTP value for
their current treatment. The time frame of pay-
ment of ‘up until menopause’ was explicitly
stated to ensure WTP values were not overesti-
mated.17 To elicit WTP, the payment scale
elicitation format was used as it has a higher com-
pletion rate than other methods that can be used
in a postal questionnaire.18 The scale range used
was £0–£500, and an open-ended option for val-
ues greater than £500 was oﬀered. To assess the
validity of the WTP responses and the respon-
dents understanding of the WTP question, we
then asked the respondent to outline reasons for
their WTP values in an open-ended question.
This approach enabled an assessment of
responses as well as providing insight into the
way in which the WTP question was interpreted.
To ensure the WTP values were realistic, that is
within the respondent’s resources, and in line with
good practice, a reminder was included asking
the women to consider the amount that they can
actually aﬀord to pay.19
Analysis
For the analysis, baseline data were taken from
the ECLIPSE trial questionnaire and post-initial
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treatment eﬀectiveness data were from the pur-
posely developed WTP questionnaire. Scores
were calculated for the baseline MMAS,
obtained from the ECLIPSE trial, and the cur-
rent (‘ex-post’) MMAS score. Similarly, baseline
and follow-up EQ-5D quality of life score was
calculated for every woman.20 Descriptive statis-
tics are reported for each measure and a paired
t-test was conducted to determine the diﬀerence
between follow-up and baseline values at the 5%
level. Cohen’s eﬀect size (mean change divided
by standard deviation) is calculated for each of
the measures where 0.2–0.5 indicates a small
change, 0.5–0.8 moderate and >0.8 large.21 As
the assessment of the validity of WTP is the aim
of this study, and not the incremental diﬀerence
between treatment arms, the WTP values for
both treatments were combined. The CUA and
CBA which consider the treatment eﬀect by
group are presented elsewhere.12,22 Thus, the
WTP for overall treatment (both LNG-IUS and
oral treatment) for menorrhagia is used to assess
the convergent validity. The association between
WTP and change in condition-speciﬁc quality of
life (MMAS), from baseline to the ex-post val-
ues, was ﬁrst assessed. Second, the association
between WTP and change in general health-
related quality of life as measured by the EQ-5D
was assessed. Finally, the association of change
in MMAS and change in EQ-5D was explored.
The associations between the measures were
assessed by Spearman’s correlation analysis.
A Rho value between 0.10 and 0.29 indicates a
small association, 0.30–0.49 medium association
and greater than 0.5 a large association.23 The
percentage improvement in MMAS from base-
line to current time point was also calculated,
using percentage improvements (<25, 26–50, 51–
75 and >75%) to establish the extent to which
WTP increased with improvement in MMAS
from baseline. The Wilcoxon rank–sum test was
carried out to identify whether the diﬀerences
between the WTP values for each percentage
change were signiﬁcant at the 5% level. The
qualitative reasons for the WTP values were fur-
ther analysed and categories generated based on
a previous published WTP study.14 The qualita-
tive information was supplemented by exploring
the inﬂuence of prominent numbers on the WTP
results. Prominent numbers are those that are
typically selected by respondents and include £0,
1, 2, 5, 10, 20, 50, 100, 200, 500 and so on.24 The
selection of prominent numbers is thought to be
related to the respondent’s perception of the dif-
ﬁculty of the task and their knowledge of the
intervention.25 Where appropriate, GBP is con-
verted to USD using a currency conversion
website www.fxexchangerate.com; (£1 = US
$0.665; 2013). We carried out all data analyses
in STATA (v11.0) and Microsoft Excel.
Results
All of the two hundred and seventy-two women
who were eligible to complete the questionnaire
in the trial received a copy. One hundred and
sixty-three questionnaires (60%) were received;
however, 78 of these questionnaires were
excluded as the women were no longer taking
either of the randomized pharmaceutical treat-
ments, and therefore, the WTP section was not
applicable to these women. Our intention was to
obtain the value for either treatment (LNG-IUS
or oral treatment) and the question posed in the
questionnaire referred to ‘current treatment’. As
these women were either no longer taking any
treatment due to menopause or other reasons, it
would not be appropriate to use values for ‘cur-
rent treatment’. However, the values of those
who have crossed over to the other treatment
are included to ensure that the values of those
who were unhappy with their original treatment
were included.
Of the remaining 85 women who returned the
questionnaire and were currently taking one of
the randomized treatments, 4 (4%) women did
not provide a WTP value and MMAS score for
their current treatment, and 11 (13%) protest
answers were identiﬁed from the qualitative
explanations oﬀered for the WTP value. Protest
responses are deﬁned as an explicit objection to
being asked to ‘pay’ for health care and there-
fore a misunderstanding of the hypothetical
nature of the exercise and are therefore invalid.
These 15 non-responses and protest answers
were removed from the analysis. It is generally
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accepted in the literature that qualitative infor-
mation associated with the protest responses
should be assessed to determine whether the val-
ues are genuine WTP values or whether the
respondent is protesting against the exercise.
There is a debate in the literature about the
inclusion of protest responses.14 Where protests
are identiﬁed, it has been argued that these
should not be included in the analysis as they are
not valid responses; however, some authors have
expressed concerns about their exclusion if the
characteristics of the excluded and included
group are not assessed.14 There were no signiﬁ-
cant diﬀerences between the characteristics of
this excluded group to the sample analysed (see
online supplementary material). In total, 70
respondents gave a WTP value for either LNG-
IUS or oral treatment and the characteristics of
this sample are presented in Table 1. The pro-
portion of respondents that had a household
income of less than £30 000 (US$45 113) was
approximately 50%, which was lower than the
national average where 65% are below approxi-
mately £27 000 (US$40 602).26
Treatment response
The average maximum WTP for treatment for
menorrhagia was approximately £27 (US$41)
per month (see Table 2). The average com-
bined MMAS score for treatment doubled
from approximately 43 at pre-treatment to 85
following treatment, generating a statistically
signiﬁcant improvement in health status as mea-
sured by this instrument (P = 0.000). According
to the Cohen’s standardized eﬀect size, the mean
eﬀect of 1.97 observed on MMAS would
indicate a large change as the eﬀect size is greater
than 0.8. Whilst average EQ-5D values increased
signiﬁcantly (P = 0.0168) from 0.789 pre-
treatment to 0.880 post-initial treatment eﬀec-
tiveness, the mean eﬀect size of 0.36 indicates a
small change using the same Cohen’s criteria
(Table 3). Whilst 0.789 pre-treatment to 0.880
post-initial treatment eﬀectiveness generates a
mean eﬀect size of 0.36 which would indicate a
small change using the same Cohen’s criteria, it
should be noted that this level of change in
EQ-5D would lead to a change in one level of
one attribute; for example, using the pain attri-
bute a change would be observed from some
pain to no pain which could be deemed clini-
cally important.
Respondent’s understanding of WTP
Among the 70 women who provided a WTP
value, 69 provided a reason for the value. Nine
categories of reasons for a WTP value were gen-
erated from the qualitative information from all
of the women, which included protests and non-
response. The categories of reasons for the sam-
ple analysed are presented in Table 4. It can be
seen that for both LNG-IUS and oral treatment
that ‘R4: aﬀordability’ and ‘R7: eﬀects of treat-
ment’ are the most commonly cited reason for a
WTP value. In addition to this ﬁnding, it can be
seen from Fig. 1, which presents the WTP values
Table 1 Sample characteristics of WTP respondents
Variable Treatment (n = 70)
Expected age of menopause (yrs) [SD] 53.80 [2.50]
Age [SD] 48.09 [3.93]
Marital status (%)
Married or living with partner 53 (76)
Not 17 (24)
Employment status (%)
Employed (FT)/(PT) 56 (80)
Not 14 (20)
Household income (%)
Less than £20 000 (<$30 075) 22 (32)
£20 001–30 000 ($30 077–$45 113) 14 (20)
£30 001–40 000 ($45 114–$60 150) 10 (14)
£40 001–50 000 ($60 152–$75 188) 9 (13)
More than £50 000 (>$75 189) 13 (20)
Main earner (%)
Yes 32 (46)
No 37 (54)
FT, full-time; PT, part-time; SD, standard deviation. (US$).
Table 2 Descriptive statistics for WTP
Valid
responses
Mean
(Median) [$] Min–Max [$] SD [$]
WTP 70 £26.99 (£10)
[$40.59 ($15)]
£0–£500
[$0–$752]
£60.73
[$91.32]
SD, standard deviation; WTP, willingness-to-pay. (US$).
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for treatment against the number of observa-
tions, that the most commonly selected WTP
values were prominent numbers, those are £10
and £20, which make up 31 and 16% of the sam-
ple which could indicate diﬃculty with the WTP
exercise or a tendency to round numbers (dis-
cussed later).
Associations
Average maximum WTP was signiﬁcantly posi-
tively correlated with change in MMAS
(P = 0.025) (Table 5). That is, the greater the
change in health state, as measured by change in
MMAS, the greater the WTP value. However,
the strength of the relationship is relatively
small, generating a rho value of 0.27. In con-
trast, the association between change in EQ-5D
and change in MMAS did not show statistical
signiﬁcance (P = 0.059), despite demonstrating
a positive correlation (r = 0.23). An unusual,
though non-signiﬁcant result is generated in the
association between WTP and change in EQ-
5D, as a minor negative correlation (r = 0.02)
is observed.
When WTP for percentage change in
MMAS is assessed, the mean WTP increases
as the change in health status increases (from
approximately £16 to £63 (US$25–US$95)).
Whilst the mean values would suggest that
WTP would continue to increase the greater
the change in health status, the median values
illustrate the skewness of the data but still
demonstrate an increase in WTP as health
status improves (Table 6). The signiﬁcance
tests show the WTP values between ‘<25%’
and ‘51–75%’ to be signiﬁcantly increased as
percentage change in MMAS increases
(P = 0.033; P < 0.05).
Discussion
In this exploratory study, we aimed to assess the
convergent validity of WTP within the context
of menorrhagia by comparing change in the con-
dition-speciﬁc measure (MMAS) to (1) change
in WTP and (2) the generic health-related
quality of life measure, EQ-5D-3L. Overall, our
Table 3 Average scores for the
instruments
Mean MMAS [SD] EQ-5D [SD] WTP ($)
Baseline (n = 70) 43.23[21.22] 0.789 [0.250]
Post-initial treatment
effectiveness (n = 70)
85.00 [23.15] 0.880 [0.215] £26.99 ($40.59)
Change (n = 70) 41.77 [32.03] 0.09 [0.31]
MMAS, Menorrhagia multi-attribute scale; SD, standard deviation; WTP, willingness-to-pay.
Table 4 Explanation given for WTP value (sample analysed,
ex-post)
Category Explanation
Total
n (%)
R2 Subject expressed difficulty
estimating WTP owing to:
Difficult to answer
Cannot put a price on health care
8 (7)
R3 WTP based on nominal amount
Arbitrary sum/guess/out of thin air
1 (0.9)
R4 WTP reflects ability to pay
(affordability)
Maximum affordable amount
given current situation
37 (35)
R5 WTP reflects reasonable value
NHS should pay but this is
a reasonable limit
8 (7)
R6 WTP reflects cost of treatment
Attempted to estimate cost
Used a comparator such
as prescription costs
5 (5)
R7 WTP reflects effect of treatment
In terms of effectiveness outcomes
In terms of process utility
30 (28)
R9 Related to cost of sanitary wear
Washing clothes/wipes/painkillers
13 (12)
R10 Misunderstood exercise but
provided WTP value
5 (5)
Total 1071
NHS; National Health Service, WTP; willingness-to-pay.
1Some respondents gave more than one reason for their WTP value.
Categories R1 and R8 were related to protest responses and are
deleted from the table as they were not included in the sample
analysed.
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ﬁndings suggest the convergent validity of WTP
as it behaves as would intuitvely be expected in
response to change in health status, as measured
by MMAS. Speciﬁcally, following treatment,
WTP increases with a greater improvement in
treatment beneﬁt, and the correlation between
the change in condition-speciﬁc MMAS and
WTP suggests statistical signiﬁcance.
An association between MMAS and the gen-
eric measure, EQ-5D, was not observed as the
change in EQ-5D scores before and after treat-
ment was not signiﬁcantly associated with the
equivalent change in MMAS. This result sug-
gests that WTP is more sensitive to change in the
condition-speciﬁc measure (MMAS), than the
generic measure (EQ-5D). We hypothesize that
this ﬁnding is attributed to the EQ-5D instru-
ment being designed as a generic health-related
quality of life measure, which is not focussed
speciﬁcally on menorrhagia. We suggest that
WTP is more sensitive given that it has the
potential to measure both health and non-health
aspects of quality of life that are important to
women who suﬀer with menorrhagia, which are
also encompassed by the MMAS measure.
Qualitative reasons for the WTP responses
provided a further opportunity to assess the reli-
ability of the WTP values. The analyses of the
reasons conﬁrmed that respondents were consid-
ering the ‘value’ of the treatment as was
theoretically expected. These values are there-
fore reﬂective of what the theory says people
consider when completing WTP exercises. How-
ever, the selection of prominent numbers could
be related to the perceived diﬃculty of the task
25 where respondents provide less precise values
when they do not feel they have adequate knowl-
edge of the good being valued.24 In this study,
the WTP values were elicited from the ex-post
perspective where respondents have experience
of, and are knowledgeable about, the treatments
and despite this, prominent numbers were most
commonly selected. This indicates that although
respondents stated ‘true’ WTP values as con-
ﬁrmed by the qualitative responses, the selection
of prominent numbers alludes to the WTP elici-
tation task being diﬃcult to complete.
Finally, as there are several possible
approaches for eliciting WTP, the method used
in the analysis reported here requires some justi-
ﬁcation. With respect to the WTP question, the
time period ‘up until menopause’ seemed intu-
itive given that menorrhagia ceases at
Figure 1 Frequency of WTP values.
Table 5 Associations between measures
Change in
MMAS (rho)
WTP
(rho)
Change in
EQ-5D (rho)
Change in MMAS 1.0000
WTP 0.2674* 1.000
Change in EQ-5D 0.2265 0.0158 1.000
*P = 0.0252 (<0.05) MMAS; menorrhagia multi-attribute scale, WTP;
willingness-to-pay.
Table 6 Mean WTP against percentage improvement in MMAS
% change
in MMAS Mean MMAS [SD] No. obs Mean WTP [SD] ($) Median ($) Min–Max WTP ($)
<25 1.27 [12.82] 21 £16.29 [£17.97] ($24.50) £10 ($15) £0–£50 ($0–75)
26–50 36.13 [8.3] 14 £20.86 [£24.65] ($31.37) £10 ($15) £6–£100 ($9–$150)
51–75 60.95 [9.04] 24 £23.38 [£20.63] ($35.16) £20 ($30) £8–£100 ($5–$150)
>75 84.44 [10.00] 11 £63.09 [£145.86] ($94.87) £20 ($30) £0–£500 ($0–$752)
MMAS; menorrhagia multi-attribute scale, SD, standard deviation; WTP; willingness-to-pay. (US$).
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menopause and the scale of £0–£500 was
thought most suitable, given that the question-
naire asked respondents to provide a monthly
WTP value. The monthly payment time frame
was used because women generally pay monthly
(or every 3 months) for prescriptions for menor-
rhagia, for sanitary protection and they
experience the beneﬁts of treatment on a
monthly basis. The out of pocket payment vehi-
cle was deemed appropriate for this context
because whilst the full price for treatment is not
paid in the UK, patients do make an out of
pocket payment for prescriptions for oral treat-
ment in the UK. Although this private payment
does not exist for LNG-IUS, the existence of pri-
vate payment within this context is likely to
minimize the issue of hypothetical bias.
To our knowledge, this is the ﬁrst study to
assess the convergent validity of WTP against a
change in condition-speciﬁc quality of life mea-
sure in menorrhagia. It is also the ﬁrst to
compare the correlation of WTP and change in
EQ-5D with a condition-speciﬁc quality of
life measure.
A limitation of this exploratory study is the
sample size used. Given that the signiﬁcant
diﬀerence was observed between the two
percentage change categories with the greatest
number of observations, it is likely that the
remaining categories were not found to be signif-
icant due to the limited sample size for the
groups ‘26–50%’ and ‘>75%’. Thus, there may
not have been suﬃcient power to detect a signiﬁ-
cant diﬀerence between these groups. The
ﬁndings from this exploratory study, however,
can be used to inform future sample size calcula-
tions for subsequent WTP studies in the area.
Prior to this study, it was not readily possible to
calculate sample size requirements as a priori
data on the distribution of WTP values for the
LNG-IUS or oral treatment were not avail-
able.27 This study therefore enables researchers
to identify the number and range of responses
given to determine how many respondents are
required to detect a certain diﬀerence in WTP
across treatments, that is the WTP value that
constitutes a meaningful diﬀerence in improve-
ments from baseline or between treatments.
To our knowledge, no other study has
assessed the sensitivity to scale of WTP accord-
ing to a longitudinal change in outcome
measured by a condition-speciﬁc measure. Other
related studies have, however, assessed the rela-
tive sensitivity of WTP and time trade-oﬀ (TTO)
for changes in described dimensions of health
states and have tentatively suggested that WTP
is sensitive to change in diﬀerent levels of health
within the same dimension.9 The sensitivity of
(ex ante) WTP with a condition-speciﬁc measure
at one time point has also been explored.28,29
Radtke et al.28 assessed the relationship between
WTP, EQ-5D and a condition-speciﬁc measure
for vitiligo; and Schiﬀner et al.29 assessed the
sensitivity of WTP and TTO with a condition-
speciﬁc measure for psoriasis. Baseline EQ-5D
(or TTO) and condition-speciﬁc scores for
current health state were identiﬁed, and hypo-
thetical WTP values were elicited for a cure.
Both studies found that WTP had a signiﬁcant
correlation with the condition-speciﬁc measure,
and Radtke et al.28 also showed WTP and EQ-
5D to have negative correlation.
Other psychometric properties of WTP and
EQ-5D in menorrhagia have also been explored.
A review of psychometric properties of measures
used in menorrhagia3 identiﬁed four key studies.
One study assessed the consistency of responses
of WTP from women with menorrhagia and
found a lack of external reliability of WTP.30
The second found EQ-5D to be unsuitable for
patients with menorrhagia.4 In the third, MMAS
was statistically associated with changes in satis-
faction post-initial treatment eﬀectiveness,
whilst EQ-5D was not.31 Finally, a lack of sensi-
tivity of EQ-5D to changes in quality of life
associated with menorrhagia was observed.32
Further research is required to consolidate
our ﬁndings using a larger sample size, the
requirements for which can now be derived
based on our study. Additional research could
explore the convergent validity of other methods
of valuation such as SF-6D in such a condition,
assessing changes in SF-6D in relation to WTP
and MMAS to determine the extent to which
SF-6D reﬂects changes in MMAS. This explora-
tory study suggests that there is the potential,
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and a beneﬁt, to the use of WTP in chronic con-
ditions with episodic symptoms which impact on
health and non-health aspects of life.
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